1. Home
  2. YXT vs KYTX Comparison

YXT vs KYTX Comparison

Compare YXT & KYTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • YXT
  • KYTX
  • Stock Information
  • Founded
  • YXT 2011
  • KYTX 2018
  • Country
  • YXT China
  • KYTX United States
  • Employees
  • YXT N/A
  • KYTX N/A
  • Industry
  • YXT
  • KYTX
  • Sector
  • YXT
  • KYTX
  • Exchange
  • YXT NYSE
  • KYTX NYSE
  • Market Cap
  • YXT 129.2M
  • KYTX 130.8M
  • IPO Year
  • YXT 2024
  • KYTX 2024
  • Fundamental
  • Price
  • YXT $1.95
  • KYTX $2.78
  • Analyst Decision
  • YXT
  • KYTX Buy
  • Analyst Count
  • YXT 0
  • KYTX 5
  • Target Price
  • YXT N/A
  • KYTX $23.20
  • AVG Volume (30 Days)
  • YXT 17.9K
  • KYTX 474.5K
  • Earning Date
  • YXT 03-04-2025
  • KYTX 03-04-2025
  • Dividend Yield
  • YXT N/A
  • KYTX N/A
  • EPS Growth
  • YXT N/A
  • KYTX N/A
  • EPS
  • YXT 3.06
  • KYTX N/A
  • Revenue
  • YXT $48,030,651.00
  • KYTX N/A
  • Revenue This Year
  • YXT N/A
  • KYTX N/A
  • Revenue Next Year
  • YXT N/A
  • KYTX N/A
  • P/E Ratio
  • YXT $0.64
  • KYTX N/A
  • Revenue Growth
  • YXT N/A
  • KYTX N/A
  • 52 Week Low
  • YXT $1.33
  • KYTX $2.65
  • 52 Week High
  • YXT $11.00
  • KYTX $30.60
  • Technical
  • Relative Strength Index (RSI)
  • YXT N/A
  • KYTX 36.42
  • Support Level
  • YXT N/A
  • KYTX $2.65
  • Resistance Level
  • YXT N/A
  • KYTX $3.11
  • Average True Range (ATR)
  • YXT 0.00
  • KYTX 0.22
  • MACD
  • YXT 0.00
  • KYTX 0.01
  • Stochastic Oscillator
  • YXT 0.00
  • KYTX 17.88

About YXT YXT.COM GROUP HOLDING LIMITED SPON ADS EA REP 3 CL A SHS

Yxt.Com Group Holding Ltd operates as a technology company. The company has created a SaaS model that integrates software and content, assisting customers in the digital transformation of corporate learning. The company operates in the People's Republic of China.

About KYTX KYVERNA THERAPEUTICS INC

Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.

Share on Social Networks: